Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised phase II trial on primary chemotherapy with high-dose Methotrexate and high-dose Cytarabine with or without Thiotepa, and with or without Rituximab, followed by brain irradiation vs high-dose chemotherapy supported by autologous stem cells transplantation for immunocompetent patients with newly diagnosed Primary CNS Lymphoma

Next Previous
Trial Profile

Randomised phase II trial on primary chemotherapy with high-dose Methotrexate and high-dose Cytarabine with or without Thiotepa, and with or without Rituximab, followed by brain irradiation vs high-dose chemotherapy supported by autologous stem cells transplantation for immunocompetent patients with newly diagnosed Primary CNS Lymphoma

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Oct 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carmustine (Primary) ; Cytarabine (Primary) ; Methotrexate (Primary) ; Rituximab (Primary) ; Thiotepa (Primary)
  • Indications CNS cancer; Lymphoma; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use

Most Recent Events

  • 16 Sep 2022 The trial has been completed in Germany, according to European Clinical Trials Database record.
  • 01 Jul 2022 7-year results published in the Leukemia
  • 14 Dec 2021 Results of a pooled analysis of management and outcome patients with rrPCNSL in the randomized trials (IELSG20 or IELSG32) presented at the 63rd American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top